Search results
Results from the WOW.Com Content Network
Drug-induced lupus erythematosus is an autoimmune disorder caused by chronic use of certain drugs. These drugs cause an autoimmune response (the body attacks its own cells) producing symptoms similar to those of systemic lupus erythematosus (SLE). There are 38 known medications to cause DIL but there are three that report the highest number of ...
Drug-induced lupus erythematosus is a (generally) reversible condition that usually occurs in people being treated for a long-term illness. Drug-induced lupus mimics SLE. However, symptoms of drug-induced lupus generally disappear once the medication that triggered the episode is stopped.
Bullous drug reaction (bullous drug eruption, generalized bullous fixed drug eruption, multilocular bullous fixed drug eruption) Chemotherapy-induced acral erythema (palmoplantar erythrodysesthesia syndrome) Chemotherapy-induced hyperpigmentation; Drug-induced acne; Drug-induced angioedema; Drug-related gingival hyperplasia
Lupus is a chronic disease that can cause inflammation and pain in any part of the body. The disease impacts about 1.5 million Americans, but women are nine times more likely to develop lupus than ...
Belimumab is primarily used in people with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...
On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ...
It is mostly well tolerated (though side effects include mucositis, diarrhea, hyperlipidemia, delayed wound healing) with drug-drug interactions. It has better activity against autoimmune disease and lymphoproliferation than mycophenolate mofetil and other drugs; however, sirolimus requires therapeutic drug monitoring and can cause mucositis.